Olaris is founded on the belief that collaborative research will lead to breakthrough science with the potential to transform human health. Contact us to learn about collaboration opportunities.


THE MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH (MJFF) is a non-profit dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. MJFF has issued a grant to Olaris, Inc to identify metabolic signatures associated with the neurodegenerative disease. Metabolic signatures may provide deeper insight into the mechanisms involved in Parkinson’s and its progression. Our mutual goal is to advance our understanding of this disease and find potential drug targets for future therapies.

Screen Shot 2019-10-28 at 5.25.54 PM.png

CARAWAY THERAPEUTICS  is developing small molecules to treat neurodegenerative and rare diseases by selectively  targeting the autophagy pathway. Autophagy is a biological process that degrades long‐lived proteins, including damaged organelles and toxic aggregates, and is fundamental to maintaining healthy cellular homeostasis; dysregulation of autophagy is hypothesized to lead to neurodegeneration. Olaris is working with Rheostat in their pre-clinical and clinical programs. 

Screen Shot 2019-06-11 at 23.23.21.png

LOULOU FOUNDATION is a non-profit dedicated to advancing research into the understanding and development of therapeutics for CDKL5 deficiency disorder. Olaris is a proud partner with the Loulou Foundation.  Olaris uses our technology to determine metabolic differences between CDKL5 wild-type and mutant neurons derived from patients. The Olaris metabolite readout will increase the biological understanding of CDKL5 function.  Further it could lead to downstream therapeutic targets and pharmacodynamic endpoints to screen therapies and de-risk and accelerate approval of novel and needed therapies for CDKL5 deficiency.

Proud Members of